LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 34

Search options

  1. Article ; Online: BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma.

    Randall, Michael P / Egolf, Laura E / Vaksman, Zalman / Samanta, Minu / Tsang, Matthew / Groff, David / Evans, J Perry / Rokita, Jo Lynne / Layeghifard, Mehdi / Shlien, Adam / Maris, John M / Diskin, Sharon J / Bosse, Kristopher R

    Journal of the National Cancer Institute

    2024  Volume 116, Issue 1, Page(s) 138–148

    Abstract: Background: High-risk neuroblastoma is a complex genetic disease that is lethal in more than 50% of patients despite intense multimodal therapy. Through genome-wide association studies (GWAS) and next-generation sequencing, we have identified common ... ...

    Abstract Background: High-risk neuroblastoma is a complex genetic disease that is lethal in more than 50% of patients despite intense multimodal therapy. Through genome-wide association studies (GWAS) and next-generation sequencing, we have identified common single nucleotide polymorphisms and rare, pathogenic or likely pathogenic germline loss-of-function variants in BARD1 enriched in neuroblastoma patients. The functional implications of these findings remain poorly understood.
    Methods: We correlated BARD1 genotype with expression in normal tissues and neuroblastomas, along with the burden of DNA damage in tumors. To validate the functional consequences of germline pathogenic or likely pathogenic BARD1 variants, we used CRISPR-Cas9 to generate isogenic neuroblastoma (IMR-5) and control (RPE1) cellular models harboring heterozygous BARD1 loss-of-function variants (R112*, R150*, E287fs, and Q564*) and quantified genomic instability in these cells via next-generation sequencing and with functional assays measuring the efficiency of DNA repair.
    Results: Both common and rare neuroblastoma-associated BARD1 germline variants were associated with lower levels of BARD1 mRNA and an increased burden of DNA damage. Using isogenic heterozygous BARD1 loss-of-function variant cellular models, we functionally validated this association with inefficient DNA repair. BARD1 loss-of-function variant isogenic cells exhibited reduced efficiency in repairing Cas9-induced DNA damage, ineffective RAD51 focus formation at DNA double-strand break sites, and enhanced sensitivity to cisplatin and poly (ADP-ribose) polymerase (PARP) inhibition both in vitro and in vivo.
    Conclusions: Taken together, we demonstrate that germline BARD1 variants disrupt DNA repair fidelity. This is a fundamental molecular mechanism contributing to neuroblastoma initiation that may have important therapeutic implications.
    MeSH term(s) Humans ; Tumor Suppressor Proteins/genetics ; Tumor Suppressor Proteins/metabolism ; Genome-Wide Association Study ; Haploinsufficiency ; Ubiquitin-Protein Ligases/genetics ; BRCA1 Protein/genetics ; DNA Repair/genetics ; Neuroblastoma/pathology
    Chemical Substances Tumor Suppressor Proteins ; Ubiquitin-Protein Ligases (EC 2.3.2.27) ; BRCA1 Protein ; BARD1 protein, human (EC 2.3.2.27)
    Language English
    Publishing date 2024-02-26
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2992-0
    ISSN 1460-2105 ; 0027-8874 ; 0198-0157
    ISSN (online) 1460-2105
    ISSN 0027-8874 ; 0198-0157
    DOI 10.1093/jnci/djad182
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Correction to: Genetic susceptibility to neuroblastoma: current knowledge and future directions.

    Ritenour, Laura E / Randall, Michael P / Bosse, Kristopher R / Diskin, Sharon J

    Cell and tissue research

    2020  Volume 383, Issue 2, Page(s) 905

    Language English
    Publishing date 2020-09-08
    Publishing country Germany
    Document type Published Erratum
    ZDB-ID 125067-x
    ISSN 1432-0878 ; 0302-766X
    ISSN (online) 1432-0878
    ISSN 0302-766X
    DOI 10.1007/s00441-020-03277-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.

    Bosse, Kristopher R / Maris, John M

    Cancer

    2016  Volume 122, Issue 1, Page(s) 20–33

    Abstract: Neuroblastoma is an embryonal malignancy that commonly affects young children and is remarkably heterogenous in its malignant potential. Recently, the genetic basis of neuroblastoma has come into focus and not only has catalyzed a more comprehensive ... ...

    Abstract Neuroblastoma is an embryonal malignancy that commonly affects young children and is remarkably heterogenous in its malignant potential. Recently, the genetic basis of neuroblastoma has come into focus and not only has catalyzed a more comprehensive understanding of neuroblastoma tumorigenesis but also has revealed novel oncogenic vulnerabilities that are being therapeutically leveraged. Neuroblastoma is a model pediatric solid tumor in its use of recurrent genomic alterations, such as high-level MYCN (v-myc avian myelocytomatosis viral oncogene neuroblastoma-derived homolog) amplification, for risk stratification. Given the relative paucity of recurrent, activating, somatic point mutations or gene fusions in primary neuroblastoma tumors studied at initial diagnosis, innovative treatment approaches beyond small molecules targeting mutated or dysregulated kinases will be required moving forward to achieve noticeable improvements in overall patient survival. However, the clonally acquired, oncogenic aberrations in relapsed neuroblastomas are currently being defined and may offer an opportunity to improve patient outcomes with molecularly targeted therapy directed toward aberrantly regulated pathways in relapsed disease. This review summarizes the current state of knowledge about neuroblastoma genetics and genomics, highlighting the improved prognostication and potential therapeutic opportunities that have arisen from recent advances in understanding germline predisposition, recurrent segmental chromosomal alterations, somatic point mutations and translocations, and clonal evolution in relapsed neuroblastoma.
    MeSH term(s) Animals ; Genome-Wide Association Study/methods ; Genome-Wide Association Study/trends ; Genomics/methods ; Genomics/trends ; Humans ; Neuroblastoma/genetics
    Language English
    Publishing date 2016-01-01
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Review
    ZDB-ID 1429-1
    ISSN 1097-0142 ; 0008-543X ; 1934-662X
    ISSN (online) 1097-0142
    ISSN 0008-543X ; 1934-662X
    DOI 10.1002/cncr.29706
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization.

    Buongervino, Samantha / Lane, Maria V / Garrigan, Emily / Zhelev, Doncho V / Dimitrov, Dimiter S / Bosse, Kristopher R

    Molecular cancer therapeutics

    2021  Volume 20, Issue 11, Page(s) 2228–2239

    Abstract: Antibody-drug conjugates (ADC) are a targeted cancer therapy that utilize the specificity of antibodies to deliver potent drugs selectively to tumors. Here we define the complex interaction among factors that dictate ADC efficacy in neuroblastoma by ... ...

    Abstract Antibody-drug conjugates (ADC) are a targeted cancer therapy that utilize the specificity of antibodies to deliver potent drugs selectively to tumors. Here we define the complex interaction among factors that dictate ADC efficacy in neuroblastoma by testing both a comprehensive panel of ADC payloads in a diverse set of neuroblastoma cell lines and utilizing the glypican 2 (GPC2)-targeting D3-GPC2-PBD ADC to study the role of target antigen density and antibody internalization in ADC efficacy in neuroblastoma. We first find that DNA binding drugs are significantly more cytotoxic to neuroblastomas than payloads that bind tubulin or inhibit DNA topoisomerase 1. We additionally show that neuroblastomas with high expression of the ABCB1 drug transporter or that harbor a
    MeSH term(s) Antibodies/metabolism ; Humans ; Immunoconjugates/pharmacology ; Immunoconjugates/therapeutic use ; Neuroblastoma/drug therapy
    Chemical Substances Antibodies ; Immunoconjugates
    Language English
    Publishing date 2021-08-31
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2063563-1
    ISSN 1538-8514 ; 1535-7163
    ISSN (online) 1538-8514
    ISSN 1535-7163
    DOI 10.1158/1535-7163.MCT-20-1034
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Immune-Based Approaches for the Treatment of Pediatric Malignancies.

    Bosse, Kristopher R / Majzner, Robbie G / Mackall, Crystal L / Maris, John M

    Annual review of cancer biology

    2019  Volume 4, Page(s) 353–370

    Abstract: Immune-based therapies have now been credentialed for pediatric cancers with the robust efficacy of chimeric antigen receptor (CAR) T cells for pediatric B cell acute lymphocytic leukemia (ALL), offering a chance of a cure for children with previously ... ...

    Abstract Immune-based therapies have now been credentialed for pediatric cancers with the robust efficacy of chimeric antigen receptor (CAR) T cells for pediatric B cell acute lymphocytic leukemia (ALL), offering a chance of a cure for children with previously lethal disease and a potentially more targeted therapy to limit treatment-related morbidities. The developmental origins of most pediatric cancers make them ideal targets for immune-based therapies that capitalize on the differential expression of lineage-specific cell surface molecules such as antibodies, antibody-drug conjugates, or CAR T cells, while the efficacy of other therapies that depend on tumor immunogenicity such as immune checkpoint inhibitors has been limited to date. Here we review the current status of immune-based therapies for childhood cancers, discuss challenges to developing immunotherapeutics for these diseases, and outline future directions of pediatric immunotherapy discovery and development.
    Language English
    Publishing date 2019-11-25
    Publishing country United States
    Document type Journal Article
    ISSN 2472-3428
    ISSN 2472-3428
    DOI 10.1146/annurev-cancerbio-030419-033436
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: BARD1

    Randall, Michael P / Egolf, Laura E / Vaksman, Zalman / Samanta, Minu / Tsang, Matthew / Groff, David / Evans, J Perry / Rokita, Jo Lynne / Layeghifard, Mehdi / Shlien, Adam / Maris, John M / Diskin, Sharon J / Bosse, Kristopher R

    bioRxiv : the preprint server for biology

    2023  

    Abstract: Importance: High-risk neuroblastoma is a complex genetic disease that is lethal in 50% of patients despite intense multimodal therapy. Our genome-wide association study (GWAS) identified single-nucleotide polymorphisms (SNPs) within the : Objective: ... ...

    Abstract Importance: High-risk neuroblastoma is a complex genetic disease that is lethal in 50% of patients despite intense multimodal therapy. Our genome-wide association study (GWAS) identified single-nucleotide polymorphisms (SNPs) within the
    Objective: To define the functional relevance of
    Design: We correlated
    Setting: (N/A).
    Participants: (N/A).
    Interventions/exposures: (N/A).
    Main outcomes and measures: BARD1
    Results: Both common and rare neuroblastoma associated
    Conclusions and relevance: Considering that at least 1 in 10 children diagnosed with cancer carry a predicted pathogenic mutation in a cancer predisposition gene, it is critically important to understand their functional relevance. Here, we demonstrate that germline
    Key points: Question:
    Language English
    Publishing date 2023-02-03
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2023.01.31.525066
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Genetic susceptibility to neuroblastoma: current knowledge and future directions.

    Ritenour, Laura E / Randall, Michael P / Bosse, Kristopher R / Diskin, Sharon J

    Cell and tissue research

    2018  Volume 372, Issue 2, Page(s) 287–307

    Abstract: Neuroblastoma, a malignancy of the developing peripheral nervous system that affects infants and young children, is a complex genetic disease. Over the past two decades, significant progress has been made toward understanding the genetic determinants ... ...

    Abstract Neuroblastoma, a malignancy of the developing peripheral nervous system that affects infants and young children, is a complex genetic disease. Over the past two decades, significant progress has been made toward understanding the genetic determinants that predispose to this often lethal childhood cancer. Approximately 1-2% of neuroblastomas are inherited in an autosomal dominant fashion and a combination of co-morbidity and linkage studies has led to the identification of germline mutations in PHOX2B and ALK as the major genetic contributors to this familial neuroblastoma subset. The genetic basis of "sporadic" neuroblastoma is being studied through a large genome-wide association study (GWAS). These efforts have led to the discovery of many common susceptibility alleles, each with modest effect size, associated with the development and progression of sporadic neuroblastoma. More recently, next-generation sequencing efforts have expanded the list of potential neuroblastoma-predisposing mutations to include rare germline variants with a predicted larger effect size. The evolving characterization of neuroblastoma's genetic basis has led to a deeper understanding of the molecular events driving tumorigenesis, more precise risk stratification and prognostics and novel therapeutic strategies. This review details the contemporary understanding of neuroblastoma's genetic predisposition, including recent advances and discusses ongoing efforts to address gaps in our knowledge regarding this malignancy's complex genetic underpinnings.
    MeSH term(s) Genetic Predisposition to Disease ; Genome-Wide Association Study ; Humans ; Mutation/genetics ; Neoplasm Proteins/genetics ; Neuroblastoma/genetics
    Chemical Substances Neoplasm Proteins
    Language English
    Publishing date 2018-03-27
    Publishing country Germany
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 125067-x
    ISSN 1432-0878 ; 0302-766X
    ISSN (online) 1432-0878
    ISSN 0302-766X
    DOI 10.1007/s00441-018-2820-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Genetic susceptibility to neuroblastoma: current knowledge and future directions

    Ritenour, LauraE / Randall, MichaelP / Bosse, KristopherR / Diskin, SharonJ

    Cell and tissue research. 2018 May, v. 372, no. 2

    2018  

    Abstract: Neuroblastoma, a malignancy of the developing peripheral nervous system that affects infants and young children, is a complex genetic disease. Over the past two decades, significant progress has been made toward understanding the genetic determinants ... ...

    Abstract Neuroblastoma, a malignancy of the developing peripheral nervous system that affects infants and young children, is a complex genetic disease. Over the past two decades, significant progress has been made toward understanding the genetic determinants that predispose to this often lethal childhood cancer. Approximately 1–2% of neuroblastomas are inherited in an autosomal dominant fashion and a combination of co-morbidity and linkage studies has led to the identification of germline mutations in PHOX2B and ALK as the major genetic contributors to this familial neuroblastoma subset. The genetic basis of “sporadic” neuroblastoma is being studied through a large genome-wide association study (GWAS). These efforts have led to the discovery of many common susceptibility alleles, each with modest effect size, associated with the development and progression of sporadic neuroblastoma. More recently, next-generation sequencing efforts have expanded the list of potential neuroblastoma-predisposing mutations to include rare germline variants with a predicted larger effect size. The evolving characterization of neuroblastoma’s genetic basis has led to a deeper understanding of the molecular events driving tumorigenesis, more precise risk stratification and prognostics and novel therapeutic strategies. This review details the contemporary understanding of neuroblastoma’s genetic predisposition, including recent advances and discusses ongoing efforts to address gaps in our knowledge regarding this malignancy’s complex genetic underpinnings.
    Keywords alleles ; carcinogenesis ; childhood ; children ; genetic disorders ; genome-wide association study ; germ cells ; high-throughput nucleotide sequencing ; infants ; mutation ; neoplasms ; peripheral nervous system ; risk assessment ; therapeutics
    Language English
    Dates of publication 2018-05
    Size p. 287-307.
    Publishing place Springer Berlin Heidelberg
    Document type Article
    Note Review
    ZDB-ID 125067-x
    ISSN 1432-0878 ; 0302-766X
    ISSN (online) 1432-0878
    ISSN 0302-766X
    DOI 10.1007/s00441-018-2820-3
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  9. Article ; Online: Improving Patient Outcomes With Cancer Genomics: Unique Opportunities and Challenges in Pediatric Oncology.

    Schnepp, Robert W / Bosse, Kristopher R / Maris, John M

    JAMA

    2015  Volume 314, Issue 9, Page(s) 881–883

    MeSH term(s) Genetic Counseling ; Humans ; Neoplasms/genetics ; Sequence Analysis, DNA/methods
    Language English
    Publishing date 2015-02-27
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
    ISSN (online) 1538-3598
    ISSN 0254-9077 ; 0002-9955 ; 0098-7484
    DOI 10.1001/jama.2015.9794
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies.

    Pascual-Pasto, Guillem / McIntyre, Brendan / Shraim, Rawan / Buongervino, Samantha N / Erbe, Amy K / Zhelev, Doncho V / Sadirova, Shakhnozakhon / Giudice, Anna M / Martinez, Daniel / Garcia-Gerique, Laura / Dimitrov, Dimiter S / Sondel, Paul M / Bosse, Kristopher R

    Journal for immunotherapy of cancer

    2022  Volume 10, Issue 12

    Abstract: Background: Antibody-drug conjugates (ADCs) that deliver cytotoxic drugs to tumor cells have emerged as an effective and safe anticancer therapy. ADCs may induce immunogenic cell death (ICD) to promote additional endogenous antitumor immune responses. ... ...

    Abstract Background: Antibody-drug conjugates (ADCs) that deliver cytotoxic drugs to tumor cells have emerged as an effective and safe anticancer therapy. ADCs may induce immunogenic cell death (ICD) to promote additional endogenous antitumor immune responses. Here, we characterized the immunomodulatory properties of D3-GPC2-PBD, a pyrrolobenzodiazepine (PBD) dimer-bearing ADC that targets glypican 2 (GPC2), a cell surface oncoprotein highly differentially expressed in neuroblastoma.
    Methods: ADC-mediated induction of ICD was studied in GPC2-expressing murine neuroblastomas in vitro and in vivo. ADC reprogramming of the neuroblastoma tumor microenvironment was profiled by RNA sequencing, cytokine arrays, cytometry by time of flight and flow cytometry. ADC efficacy was tested in combination with macrophage-driven immunoregulators in neuroblastoma syngeneic allografts and human patient-derived xenografts.
    Results: The D3-GPC2-PBD ADC induced biomarkers of ICD, including neuroblastoma cell membrane translocation of calreticulin and heat shock proteins (HSP70/90) and release of high-mobility group box 1 and ATP. Vaccination of immunocompetent mice with ADC-treated murine neuroblastoma cells promoted T cell-mediated immune responses that protected animals against tumor rechallenge. ADC treatment also reprogrammed the tumor immune microenvironment to a proinflammatory state in these syngeneic neuroblastoma models, with increased tumor trafficking of activated macrophages and T cells. In turn, macrophage or T-cell inhibition impaired ADC efficacy in vivo, which was alternatively enhanced by both CD40 agonist and CD47 antagonist antibodies. In human neuroblastomas, the D3-GPC2-PBD ADC also induced ICD and promoted tumor phagocytosis by macrophages, which was further enhanced when blocking CD47 signaling in vitro and in vivo.
    Conclusions: We elucidated the immunoregulatory properties of a GPC2-targeted ADC and showed robust efficacy of combination immunotherapies in diverse neuroblastoma preclinical models.
    MeSH term(s) Humans ; Mice ; Animals ; Glypicans ; Immunoconjugates/pharmacology ; Immunoconjugates/therapeutic use ; CD47 Antigen ; Neuroblastoma/drug therapy ; Macrophages ; Tumor Microenvironment
    Chemical Substances Glypicans ; Immunoconjugates ; CD47 Antigen
    Language English
    Publishing date 2022-12-02
    Publishing country England
    Document type Journal Article
    ZDB-ID 2719863-7
    ISSN 2051-1426 ; 2051-1426
    ISSN (online) 2051-1426
    ISSN 2051-1426
    DOI 10.1136/jitc-2022-004704
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top